Recent APLS News
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress • GlobeNewswire Inc. • 05/24/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:03:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:09:03 PM
- Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 09:15:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2024 09:13:42 PM
- Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:02:51 AM
- Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference • GlobeNewswire Inc. • 05/06/2024 11:00:00 AM
- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) • GlobeNewswire Inc. • 04/26/2024 11:15:00 AM
- Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/23/2024 11:00:14 AM
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/04/2024 08:05:00 PM
- Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:08:32 PM
- Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:10:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 12:45:34 PM
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:07:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:04:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:25:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:37:33 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/29/2024 10:10:01 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 12:35:40 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM